BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024

Simon Collins, HIV i-Base

In July 2024, Bristol Myers Squibb (BMS) announced plans to discontinue the coformulation of atazanavir/cobicistat (Evotaz) on 30 September 2024.

This is due to declining sales and the availability of newer options for ART.

It is also due to availability of generic versions of each drug.

Doctors are being asked to review anyone currently receiving atazanavir/cobicistat as part of their antiretroviral regimen.

Please contact the BMS Medical Information Department for further information by email or call 0800 731 1736.

Links to other websites are current at date of posting but not maintained.